产品
编 号：F486759
分子式：C11H11F3NNaO6S2
分子量：397.32
分子式：C11H11F3NNaO6S2
分子量：397.32
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 865625-56-5
产品详情
生物活性：
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
体内研究：
Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure.Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice.Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection.Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts.Animal Model:Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)
Dosage:10 mg/kg
Administration:P.o. once a day at days 2, 3 and 4 post-infection
Result:Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.
体外研究：
Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC50 at 0.7 nM).
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
体内研究：
Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure.Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice.Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection.Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts.Animal Model:Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)
Dosage:10 mg/kg
Administration:P.o. once a day at days 2, 3 and 4 post-infection
Result:Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.
体外研究：
Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC50 at 0.7 nM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备